CTT Pharmaceutical Holdings, Inc. has disclosed a significant stock transaction involving its CEO, Ryan Khouri. On October 26, 2026, Khouri acquired 5,880 shares of the company, reflecting a price of $0.057 per share. This transaction is noteworthy as it demonstrates the CEO's confidence in the company's future prospects and aligns with the interests of shareholders.
CTT Pharmaceutical Holdings, Inc. operates in the pharmaceutical preparations sector, classified under SIC 2834. The company is listed on the OTC exchange under the ticker CTTH. CTT has undergone several name changes in the past, with its current name adopted in 2011. The firm is categorized as a non-accelerated filer and is recognized as a smaller reporting company and an emerging growth company.
According to the recent SEC filing, Khouri's acquisition of shares brings his total ownership to 9,442,536 shares. This transaction was filed under accession number 0001035422-26-000018. The filing indicates that Khouri is both a director and an officer of the company, holding the title of CEO.
The impact of this transaction may resonate with investors and stakeholders, as it underscores the leadership's commitment to the company's growth and stability. In a competitive industry like pharmaceutical preparations, such actions can influence market perceptions and investor confidence.
The filing does not specify what happens next regarding further transactions or corporate actions.